x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011974
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human DMT1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SLC11A2 |
| UniProt No. | P49281 |
| Gene ID | 4891 |
| Gene Description | Divalent metal-ion transporter 1 is a transmembrane metal ion transport protein that plays critical roles in non-heme iron absorption in the intestine and iron acquisition by erythroid precursor cells. Following the cellular uptake of iron, DMT1 transfers ferric iron from the endosomes to the cytoplasm. The DMT1 protein can transport up to eight different metals, including iron, manganese, cobalt, and cadmium. Four mammalian DMT1 isoforms are expressed in various tissues and are differentially regulated at both the transcriptional and post-translational level. Mutations in the corresponding SLC11A2 gene can result in hypochromic microcytic anemia and iron overload. Aberrant iron transport in these individuals results in erythroid hyperplasia, high serum iron, and impaired liver function. Research studies show elevated DMT1 levels and iron accumulation in the substantia nigra of Parkinson's disease patients and the corresponding animal model. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
